Alamar Biosciences and Nightingale Health have initiated the UK Biobank PRISM study, analyzing 80,000 blood samples to identify early protein biomarkers linked to neurodegenerative diseases like Parkinson's and Alzheimer's. Using Alamar's sensitive NULISA platform, the study aims to uncover molecular signals years before symptoms appear, potentially enabling earlier diagnosis and treatment. Funded by major foundations, the project will complete by 2027 and provide open-access data to researchers worldwide, advancing understanding and prevention of these diseases.
The UK Biobank PRISM study on neurodegenerative diseases involves analyzing 80,000 blood samples to find early protein biomarkers. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 06:32 WIB: out of 150 priced US health stocks, 54 rose and 94 fell. Notable movers include MRVI at USD 7.15 with a -8.45% change, HIMS at USD 25.37 with a -8.35% change and 100% buy order activity, and RMD at USD 231.76 with a -8.33% change and a typical hold time of 52 days.
Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...
Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
